BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,070 filers reported holding BAXTER INTL INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $226,113 | -63.8% | 5,991 | -56.3% | 0.01% | -58.8% |
| Q2 2023 | $624,278 | +117.1% | 13,702 | +93.3% | 0.02% | +112.5% |
| Q1 2023 | $287,582 | +5.7% | 7,090 | +40.4% | 0.01% | -79.5% |
| Q3 2022 | $272,000 | +21.4% | 5,051 | +45.0% | 0.04% | +34.5% |
| Q2 2022 | $224,000 | -18.8% | 3,483 | -2.1% | 0.03% | -14.7% |
| Q1 2022 | $276,000 | -48.5% | 3,557 | -43.0% | 0.03% | -43.3% |
| Q4 2021 | $536,000 | +147.0% | 6,242 | +131.3% | 0.06% | +81.8% |
| Q3 2021 | $217,000 | -62.8% | 2,699 | -62.3% | 0.03% | -5.7% |
| Q1 2019 | $583,000 | +30.7% | 7,164 | +5.7% | 0.04% | -39.7% |
| Q4 2018 | $446,000 | +49.2% | 6,779 | +67.2% | 0.06% | +163.6% |
| Q2 2018 | $299,000 | +25.1% | 4,054 | +9.8% | 0.02% | -4.3% |
| Q4 2017 | $239,000 | +11.7% | 3,693 | +4.4% | 0.02% | -8.0% |
| Q2 2017 | $214,000 | -56.8% | 3,537 | -66.0% | 0.02% | -89.6% |
| Q3 2016 | $495,000 | -52.3% | 10,392 | -54.7% | 0.24% | -56.8% |
| Q2 2016 | $1,037,000 | +20.2% | 22,943 | +9.2% | 0.56% | +5.5% |
| Q1 2016 | $863,000 | -78.5% | 21,019 | -80.0% | 0.53% | +11.4% |
| Q4 2015 | $4,018,000 | +1899.0% | 105,322 | +3557.0% | 0.48% | +148.7% |
| Q2 2015 | $201,000 | – | 2,880 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |